A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
ApexOnco Front Page
Recent articles
So who else could be interested in the oestrogen degrader?
The group cans ZW171 after “on-target, off-tumour toxicity”.
Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.
As pivotal data approach, the French group pays $210m for ex-US rights.
Duality takes its Adam9-targeting conjugate into the clinic.
It’s a new term for biotech and its investors.
Pumitamig is the latest to be tested in first-line disease.
